ARTICLE | Politics, Policy & Law
Back to School 2018: A pathway to Biopharma 3.0
Back to School 2018: How external disrupters will drive biopharma to new business model
September 1, 2018 3:01 AM UTC
As market and social forces continue to tighten around the biopharmaceutical industry, drug companies need to start evolving toward a new business model that both capitalizes on the potential of new technologies and accommodates society’s demands for better, cheaper drugs that are broadly accessible.
This means laying the groundwork for what would be the industry’s third business model in nearly 40 years...